psychedelic news

As MDMA nears FDA approval, LSD’s efficacy in treating generalized anxiety disorder is demonstrated in MindMed’s Phase 2b study. Meanwhile, Congress has approved a psychedelic treatment bill for active duty service members suffering from PTSD.

The evidence pile for psilocybin’s efficacy in treating depression is growing with new data demonstrating 79% remission rates after two doses. Meanwhile, early trials hint at MEAI’s efficacy in treating obesity, ketamine studies suggest a single dose is effective in treating anxiety and discussions arise about psychedelic use and its capacity to birth new environmentalists.

Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a “both and” approach to treating ADHD.

Psilocybin can be an useful tool when it comes to reducing nicotine withdrawal, PTSD, and even OCD symptoms. It could also be a hazardous weapon for those who suffer from personality disorders.

While everyone was preparing to head to Wonderland Miami, the psychedelic space saw a week full of debates! From the FDA’s recommendation to limit psychological support in clinical trials, to debates over the necessity of the ‘trip’ in the psychedelic experience, to whether microdosing’s benefits are influenced by expectancy bias.

While unprecedented positive results provide further proof of psilocybin’s anti-depressive effects, other studies investigate the long-term adverse effects of challenging trips. Meanwhile, the DEA wants to increase the manufacturing of certain psychedelics yet again as more psychedelic dispensaries are getting raided in Canada.